Feeley Kevin sold $19K of WGS

Casdin Capital, LLC purchased 200,000 indirectly-held shares of GeneDx Holdings Corp. (WGS) at an average of $55.55 ($52.86–$56.44, $11.11M total) across 2 trades over 2026-06-04 to 2026-06-05.

GeneDx Holdings (NASDAQ: WGS) shares fell 49% on May 5, 2025 after the company reported a Q1 2026 earnings miss, a tenfold increase in net loss, and cut full-year 2026 guidance by 12%, according to the report. Hagens Berman opened a securities-law investigation, citing a shift in product mix and reduced growth expectations. The article notes ARR was $3,750 in 2025 and was expected to be flat for 2026.

GeneDx Holdings Corp. has issued its definitive proxy statement (DEF 14A) for its 2026 virtual annual meeting on June 18, 2026. Stockholders will vote on the election of one Class II director, the ratification of Ernst & Young LLP as auditor, non-binding advisory approval of executive compensation, and the frequency of future say-on-pay votes. The proxy statement details the company's strong 2025 financial performance, including significant revenue growth and adjusted net income, and outlines the executive compensation philosophy which emphasizes a pay-for-performance culture through a mix of base salary, annual cash incentives, and long-term equity incentives, including performance-based restricted stock units (PRSUs).

An insider at WGS (NASDAQ: WGS) has filed a Form 144, indicating proposed dispositions of Class A Common Stock. The filing details multiple sales reported in early 2026, totaling over 22,000 shares across several dates, originating from restricted stock units acquired between 2022 and 2023. Morgan Stanley Smith Barney is listed as the broker and NASDAQ as the market for these transactions.

A recent Form 144 filing for GeneDx Holdings Corp. (NASDAQ: WGS) indicates multiple proposed sales of Class A common stock by affiliate Katherine Stueland during 2026. The filing details several sales derived from Restricted Stock Units, along with the individual quantities sold and Stueland's remaining holdings after each transaction. These are routine disclosures of equity compensation dispositions rather than corporate actions.

GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units (RSUs) and subsequently sold 46,933 shares to cover tax withholding obligations. These "sell to cover" transactions were non-discretionary and executed at weighted average prices between $60.93 and $65.61 per share. After these transactions, the CEO beneficially owns 91,514 shares of Class A common stock, along with additional RSUs and stock options.